DIAGNOS Announces HIPAA Compliance for the US market
June 06 2019 - 09:00AM
DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we”) (TSX Venture:
ADK) (OTCQB: DGNOD), a leader in early detection of critical health
issues through the use of its FL
AIRE platform
based on Artificial Intelligence (
AI), announces
today that its quality management system now fully complies with
the requirements of the Health Insurance Portability and
Accountability Act (“HIPAA”).
HIPAA sets the standard for sensitive patient
data protection. DIAGNOS has put in place the necessary physical
network, and process security measures to ensure HIPAA Compliance.
Covered entities (anyone providing treatment, payment, and
operations in healthcare) and business associates (anyone who has
access to patient information and provides support in treatment,
payment, or operations) must meet HIPAA Compliance.
In the coming months, DIAGNOS will be addressing
the US market with a new release of its early detection algorithms
and will be seeking an updated Food and Drug Administration
clearance on them. “As we reinforce our CARA solution with
this most powerful release, we are making sure that we are
compliant with all regulatory processes for a full deployment
across the USA in the coming year,” said Mr. André Larente,
President of DIAGNOS.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America, is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS IncTel:
450-678-8882 ext. 224alarente@diagnos.ca
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements.DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2023 to Mar 2024